	US 11,692,172 B2
	Formulation comprising extracellular vesicles, method for producing the same, and uses thereof
Kuen-Der Yang, Taichung (TW); Yeou-Ping Tsao, Taipei (TW); and Chie-Pein Chen, Taipei (TW)
Assigned to MACKAY MEMORIAL HOSPTAL, Taipei (TW)
Filed by MacKay Memorial Hospital, Taipei (TW)
Filed on Jun. 26, 2018, as Appl. No. 16/18,055.
Claims priority of provisional application 62/524,624, filed on Jun. 26, 2017.
Prior Publication US 2018/0371418 A1, Dec. 27, 2018
Int. Cl. C12N 5/0775 (2010.01); C12N 5/073 (2010.01); C12N 15/113 (2010.01); A61K 38/17 (2006.01); A61K 31/713 (2006.01); A61K 9/50 (2006.01); C12N 15/11 (2006.01); A61K 41/10 (2020.01); A61K 35/28 (2015.01); A61K 41/17 (2020.01); A61P 35/00 (2006.01); A61P 9/00 (2006.01); A61P 29/00 (2006.01)

CPC C12N 5/0665 (2013.01) [A61K 9/50 (2013.01); A61K 9/5068 (2013.01); A61K 31/713 (2013.01); A61K 35/28 (2013.01); A61K 38/179 (2013.01); A61K 41/10 (2020.01); A61K 41/17 (2020.01); C12N 5/0605 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); A61P 9/00 (2018.01); A61P 29/00 (2018.01); A61P 35/00 (2018.01); C12N 2310/141 (2013.01); C12N 2320/32 (2013.01); C12N 2500/02 (2013.01); C12N 2500/30 (2013.01); C12N 2501/65 (2013.01)]

4 Claims

1. A method of treating a degenerative disease in a subject, comprising administering to the subject an effective amount of a formulation including an extracellular vesicle (EV) derived from a mesenchymal stem cell and curcumin encapsulated in the EV, wherein the mesenchymal stem cell is isolated from Wharton jelly of umbilical cord, and is CD29⁺, CD34⁻, CD44⁺ and CD73⁺, and wherein the formulation is prepared by:

(a-2) culturing the mesenchymal stem cell in the presence of aspirin;

(b-2) culturing the mesenchymal stem cell obtained in step (a-2) under 1% to 5% O₂and in serum free medium;

(c-2) isolating the EV from the cultured mesenchymal stem cell obtained in step (b-2); and

(d-2) encapsulating the curcumin in the isolated EV obtained in step (c-2).